Ziccum AB (publ) (ZICC.ST)
SEK 0.25
(0.0%)
SEK 0.25
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.34 Million SEK | 2.69% |
| 2022 | -27.58 Million SEK | -16.14% |
| 2021 | -20.27 Million SEK | -20.36% |
| 2020 | -16.84 Million SEK | -98.87% |
| 2019 | -8.67 Million SEK | -112.6% |
| 2018 | -3.98 Million SEK | -2198.45% |
| 2017 | -173.33 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -5.6 Million SEK | 23.25% |
| 2024 Q1 | -3.71 Million SEK | 49.76% |
| 2024 Q2 | -7.61 Million SEK | -96.56% |
| 2023 FY | - SEK | 2.69% |
| 2023 Q3 | -3.59 Million SEK | 24.43% |
| 2023 Q2 | -4.75 Million SEK | -2.65% |
| 2023 Q1 | -4.63 Million SEK | 13.58% |
| 2023 Q4 | -8.01 Million SEK | -122.93% |
| 2022 Q1 | -6.01 Million SEK | 2.72% |
| 2022 FY | - SEK | -16.14% |
| 2022 Q4 | -5.36 Million SEK | 2.19% |
| 2022 Q3 | -5.48 Million SEK | 17.99% |
| 2022 Q2 | -6.68 Million SEK | -11.03% |
| 2021 Q4 | -6.18 Million SEK | -28.71% |
| 2021 Q3 | -4.8 Million SEK | 4.32% |
| 2021 Q2 | -5.02 Million SEK | -18.02% |
| 2021 Q1 | -4.25 Million SEK | -36.97% |
| 2021 FY | - SEK | -20.36% |
| 2020 FY | - SEK | -98.87% |
| 2020 Q3 | -5.22 Million SEK | -13.17% |
| 2020 Q4 | -3.1 Million SEK | 40.49% |
| 2020 Q2 | -4.61 Million SEK | -18.39% |
| 2020 Q1 | -3.89 Million SEK | -18.91% |
| 2019 Q4 | -3.27 Million SEK | -148.9% |
| 2019 Q3 | -1.31 Million SEK | 41.07% |
| 2019 Q2 | -2.23 Million SEK | -37.29% |
| 2019 Q1 | -1.62 Million SEK | 4.68% |
| 2019 FY | - SEK | -112.6% |
| 2018 Q1 | -102 Thousand SEK | -78.95% |
| 2018 Q2 | -521 Thousand SEK | -410.78% |
| 2018 FY | - SEK | -2198.45% |
| 2018 Q4 | -1.7 Million SEK | -3.33% |
| 2018 Q3 | -1.65 Million SEK | -217.27% |
| 2017 Q2 | -8000.00 SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | -57 Thousand SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 94.469% |
| AcouSort AB (publ) | -16.7 Million SEK | -21.787% |
| Active Biotech AB (publ) | -43.88 Million SEK | 53.649% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 48534.487% |
| Amniotics AB (publ) | -27.14 Million SEK | 25.056% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -43.082% |
| BioArctic AB (publ) | 275.38 Million SEK | 107.387% |
| Camurus AB (publ) | 562.54 Million SEK | 103.616% |
| Cantargia AB (publ) | -284.31 Million SEK | 92.845% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -3.897% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -19.067% |
| Genovis AB (publ.) | 64.57 Million SEK | 131.503% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 82.297% |
| Mendus AB (publ) | -97.84 Million SEK | 79.21% |
| Kancera AB (publ) | -61.88 Million SEK | 67.131% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 24.049% |
| LIDDS AB (publ) | -39.67 Million SEK | 48.722% |
| Lipum AB (publ) | -37.11 Million SEK | 45.198% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -68.06% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 164.775% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1017200.0% |
| NextCell Pharma AB | -40.98 Million SEK | 50.367% |
| OncoZenge AB (publ) | 7.26 Million SEK | 379.961% |
| Saniona AB (publ) | -69.69 Million SEK | 70.813% |
| Simris Alg AB (publ) | -22.36 Million SEK | 9.037% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 93.592% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 92.787% |
| Xintela AB (publ) | -53.47 Million SEK | 61.957% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 45.057% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 88.021% |
| CombiGene AB (publ) | -35.33 Million SEK | 42.433% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 85.558% |
| Intervacc AB (publ) | -68.98 Million SEK | 70.51% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 91.439% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -877.981% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -51.456% |
| Corline Biomedical AB | -1.69 Million SEK | -1102.957% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 88.264% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 62.884% |
| Aptahem AB (publ) | -10 Million SEK | -103.232% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 276.136% |
| Fluicell AB (publ) | -25.91 Million SEK | 21.502% |
| Biovica International AB (publ) | -119.5 Million SEK | 82.978% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 51.824% |
| Abliva AB (publ) | -93.6 Million SEK | 78.269% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 93.625% |
| 2cureX AB (publ) | -35.13 Million SEK | 42.105% |
| I-Tech AB | 30.34 Million SEK | 167.036% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 97.153% |
| Cyxone AB (publ) | -20.41 Million SEK | 0.353% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 80.145% |
| Biosergen AB | 228 Thousand SEK | 9021.93% |
| Nanologica AB (publ) | -62.11 Million SEK | 67.253% |
| SynAct Pharma AB | -222.7 Million SEK | 90.866% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 53.622% |
| BioInvent International AB (publ) | -312.7 Million SEK | 93.495% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 6674.384% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 91.218% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -130.832% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 81.262% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -77.365% |